Merck & Co. Inc.

11/30/2021 | Press release | Distributed by Public on 11/30/2021 05:47

Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent[...]